Sanofi SA reported net sales of €9 billion in the 2012 third quarter, up by 3.3% on a reported basis, but down 3.1% at constant exchange rates. The expiry of a patent on a chemotherapy drug was a drag on revenue. But new products were 70% of sales. ---Subscribe to MedNous to access this article--- Company News
